Literature DB >> 7533620

Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase.

B E Crack1, C E Pollard, M W Beukers, S M Roberts, S F Hunt, A H Ingall, K C McKechnie, A P IJzerman, P Leff.   

Abstract

1. FPL 67156 (6-N,N-diethyl-beta, gamma-dibromomethylene-D-ATP), is a newly synthesized analogue of ATP. 2. In a rabbit isolated tracheal epithelium preparation, measuring P2U-purinoceptor-dependent chloride secretion, FPL 67156 was discovered to potentiate the responses to UTP but not those to ATP-gamma-S. UTP agonist-concentration effect (E/[A]) curves were shifted to the left by 5-fold in the presence of 100 microM FPL 67156. The differential effect of FPL 67156 on UTP and ATP-gamma-S was hypothesized to be due to the greater susceptibility of UTP to enzymatic dephosphorylation and the ability of FPL 67156 to inhibit this process. 3. FPL 67156 was tested as an ecto-ATPase inhibitor in a human blood cell assay, measuring [gamma 32P]-ATP dephosphorylation. The compound inhibited [gamma 32P]-ATP degradation with a pIC50 of 4.6. 4. FPL 67156 was then tested for its effects on ATP and alpha, beta-methylene-ATP responses at P2X-purinoceptors in the rabbit isolated ear artery. In the concentration range 30 microM-1 mM, the compound potentiated the contractile effects of ATP but not those of alpha, beta-methylene-ATP. At 1 mM, FPL 67156 produced a 34-fold leftward shift of ATP E/[A] curves. 5. The effects of FPL 67156 on ATP E/[A] curves in the rabbit ear artery were analyzed using a theoretical model (Furchgott, 1972) describing the action of an enzyme inhibitor on the effects of a metabolically unstable agonist. This analysis provided an estimate of the pKi for FPL 67156 as an ecto-ATPase inhibitor of 5.2. 6. Using appropriate assays, FPL 67156 was shown to have weak antagonist effects at P2X- and P2T-purinoceptors (pA2 ~ 3.3 and 3.5 respectively), and weak agonist effects at P2u-purinoceptors(p[A 50]~ 3.5).7. The degree of potentiation of ATP and UTP effects elicited by FPL 67156 confirms previous results concerning the influence that ecto-ATPase has on the position of E/[A] curves for metabolically unstable agonists. The magnitude of this influence is predicted to have a major effect on the agonist potency orders currently used to designate purinoceptors.8.This study indicates FPL 67156 to be a potentially valuable probe in studies on the action of nucleotides and in the classification of purinoceptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533620      PMCID: PMC1510226          DOI: 10.1111/j.1476-5381.1995.tb13251.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

1.  Characterization of P2x-receptors in rabbit isolated ear artery.

Authors:  S E O'Connor; B E Wood; P Leff
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  Suramin is a slowly-equilibrating but competitive antagonist at P2x-receptors in the rabbit isolated ear artery.

Authors:  P Leff; B E Wood; S E O'Connor
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

3.  The relationship between cholinesterase inhibition in the chick biventer cervicis muscle and its sensitivity to exogenous acetylcholine.

Authors:  A L Green; J A Lord; I G Marshall
Journal:  J Pharm Pharmacol       Date:  1978-07       Impact factor: 3.765

4.  The structure-activity relationships of ectonucleotidases and of excitatory P2-purinoceptors: evidence that dephosphorylation of ATP analogues reduces pharmacological potency.

Authors:  L A Welford; N J Cusack; S M Hourani
Journal:  Eur J Pharmacol       Date:  1987-09-02       Impact factor: 4.432

Review 5.  Is there a basis for distinguishing two types of P2-purinoceptor?

Authors:  G Burnstock; C Kennedy
Journal:  Gen Pharmacol       Date:  1985

6.  The potentiation of the responses to noradrenaline and isoprenaline of the guinea-pig isolated tracheal chain preparation by desipramine, cocaine, phentolamine, phenoxybenzamine, guanethidine, metanephrine and cooling.

Authors:  R W Foster
Journal:  Br J Pharmacol Chemother       Date:  1967-11

7.  FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors.

Authors:  R G Humphries; W Tomlinson; A H Ingall; P A Cage; P Leff
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

8.  Quantitative estimation of overadditive and underadditive drug effects by means of theoretical, additive dose-response curves.

Authors:  G Pöch; S Holzmann
Journal:  J Pharmacol Methods       Date:  1980-09

9.  Errors in the measurement of agonist potency-ratios produced by uptake processes: a general model applied to beta-adrenoceptor agonists.

Authors:  T P Kenakin
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

10.  Purine receptors in trachea: studies with adenosine deaminase and dipyridamole.

Authors:  D Satchell
Journal:  Eur J Pharmacol       Date:  1984-07-20       Impact factor: 4.432

View more
  51 in total

1.  Release of a soluble ATPase from the rabbit isolated vas deferens during nerve stimulation.

Authors:  T D Westfall; J R Menzies; R Liberman; S Waterston; N Ramphir; D P Westfall; P Sneddon; C Kennedy
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

2.  Methylene ATP analogs as modulators of extracellular ATP metabolism and accumulation.

Authors:  Sheldon M Joseph; Matthew A Pifer; Ronald J Przybylski; George R Dubyak
Journal:  Br J Pharmacol       Date:  2004-06-21       Impact factor: 8.739

3.  Enhancement of spontaneous synaptic activity in rat Purkinje neurones by ATP during development.

Authors:  Diana Casel; Johannes Brockhaus; Joachim W Deitmer
Journal:  J Physiol       Date:  2005-07-07       Impact factor: 5.182

4.  Generation and characterization of polyclonal and monoclonal antibodies to human NTPDase2 including a blocking antibody.

Authors:  Julie Pelletier; Hervé Agonsanou; Ninotchska Delvalle; Michel Fausther; Mabrouka Salem; Brian Gulbransen; Jean Sévigny
Journal:  Purinergic Signal       Date:  2017-04-13       Impact factor: 3.765

5.  Role of P2 purinergic receptors in synaptic transmission under normoxic and ischaemic conditions in the CA1 region of rat hippocampal slices.

Authors:  Elisabetta Coppi; Anna Maria Pugliese; Holger Stephan; Christa E Müller; Felicita Pedata
Journal:  Purinergic Signal       Date:  2007-01-03       Impact factor: 3.765

6.  A capillary electrophoresis method for the characterization of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the analysis of inhibitors by in-capillary enzymatic microreaction.

Authors:  Jamshed Iqbal; Petra Vollmayer; Norbert Braun; Herbert Zimmermann; Christa E Müller
Journal:  Purinergic Signal       Date:  2005-12-03       Impact factor: 3.765

7.  Enhancement of sympathetic purinergic neurotransmission in the guinea-pig isolated vas deferens by the novel ecto-ATPase inhibitor ARL 67156.

Authors:  T D Westfall; C Kennedy; P Sneddon
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

8.  Responses of the longitudinal muscle and the muscularis mucosae of the rat duodenum to adenine and uracil nucleotides.

Authors:  C R Johnson; S J Charlton; S M Hourani
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

9.  8-BuS-ATP derivatives as specific NTPDase1 inhibitors.

Authors:  Joanna Lecka; Irina Gillerman; Michel Fausther; Mabrouka Salem; Mercedes N Munkonda; Jean-Philippe Brosseau; Christine Cadot; Mireia Martín-Satué; Pedro d'Orléans-Juste; Eric Rousseau; Donald Poirier; Beat Künzli; Bilha Fischer; Jean Sévigny
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

10.  P2-purinoceptor-mediated formation of inositol phosphates and intracellular Ca2+ transients in human coronary artery smooth muscle cells.

Authors:  D Strøbaek; S P Olesen; P Christophersen; S Dissing
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.